The GLP-1 Fallout: What the FDA Ban Means for Obesity Treatment

GLP-1s like Ozempic and Zepbound transformed obesity and diabetes treatment. But when shortages hit, compounding pharmacies and telehealth startups filled the gap with off-brand versions—cheap, accessible, and often unregulated.

Now, that workaround is over.

In this episode, we examine the FDA’s sweeping May 2025 ban on compounded GLP-1 drugs. What triggered it? What are the safety risks? And why is the industry suddenly pivoting to an older, less effective drug: liraglutide?

With interviews, data, and regulatory context, we break down:

• Why Olympia Pharmaceuticals stopped producing semaglutide
• Why liraglutide is gaining traction despite its limitations
• What the FDA has reported about dosing errors, hospitalizations, and even deaths
• How insurance gaps and policy shifts continue to limit access
• What healthcare professionals should consider when restarting patients or navigating new formularies

This isn’t just a regulatory update—it’s a turning point in the story of obesity treatment in America.